ArticleBMC endocrine disorders2026
Associations between genetic variants of vitamin D metabolic pathway and gestational diabetes mellitus: the potential mediation role of serum 25(OH)D
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCirculating vitamin D concentrations have been recognized as a risk factor for GDM. The pathway genes of vitamin D synthesis and metabolism have been shown to be strongly associated with serum vitamin D. This study aimed to evaluate the association between genetic variations and GDM risk, and to further explore the potential mediating role of serum 25(OH)D3 in these relationships.
methodsA nested case-control study including 131 cases of GDM and 131 controls from the Zhengzhou Birth Cohort established since 2021. We genotyped nine SNPs using the TaqMan probe method and measured serum 25(OH)D3 by ELISA.
resultsThe VDR rs731236-G allele was associated with reduced GDM risk: the OR (95% CI) was 0.56 (0.34, 0.93) in the multivariable adjusted model. Conversely, the VDR rs7975232-A allele was associated with a higher risk of GDM (OR: 1.56; 95% CI: 1.04, 2.33). Higher 25(OH)D3 levels were inversely associated with GDM risk (OR: 0.36; 95% CI: 0.20, 0.67; Ptrend <0.01). Each 1-unit increment of log-transformed 25(OH)D3 level was associated with a 79% lower risk of GDM (OR 0.21, 95% CI: 0.09, 0.46). Mediation analyses indicated that 25(OH)D3 explained 24.7% of the protective effect of the VDR rs731236 variant [Indirect effect= -0.06 (-0.12, -0.01)], and 29.6% of the detrimental effect of VDR rs7975232 and GDM risk [indirect effect = 0.07 (0.03, 0.13)].
conclusionsThe study suggested a significant association of VDR rs7975232 and rs731236 polymorphisms with GDM risk among the Chinese population. Higher 25(OH)D3 levels were associated with a decreased risk of GDM. Additionally, circulating 25(OH)D3 partially mediated the association between variant genotype of SNPs at VDR-rs731236 and VDR-rs7975232 and GDM risk, but the relatively wide CI prompted cautious interpretation. These findings emphasize the important role of genetic variants in VDR in the pathogenesis of GDM. Further studies with larger cohort sample sizes should be conducted to confirm the present findings. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.